Trial Outcomes & Findings for Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS) (NCT NCT01220557)

NCT ID: NCT01220557

Last Updated: 2021-08-17

Results Overview

Difference between baseline A1c and A1c at 6 month follow up. Equivalent effect on glycemic control measured by A1c (non-inferiority). In case of-non-inferiority test of superiority.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

160 participants

Primary outcome timeframe

Baseline and 6 months

Results posted on

2021-08-17

Participant Flow

The participants were recruited in 23 outpatient study centres, which were located all over Germany. A study centre was defined as a medical practice run by a diabetologist and a diabetes educator or diabetes nurse.

Participant milestones

Participant milestones
Measure
PRIMAS Group
PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
Control Group
The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
Overall Study
STARTED
81
79
Overall Study
COMPLETED
75
74
Overall Study
NOT COMPLETED
6
5

Reasons for withdrawal

Reasons for withdrawal
Measure
PRIMAS Group
PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
Control Group
The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
Overall Study
Lost to Follow-up
5
3
Overall Study
attended less than 6 lessons
1
2

Baseline Characteristics

Evaluation of a Treatment and Education Programme for Type 1 Diabetic Patients (PRIMAS)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
PRIMAS Group
n=81 Participants
PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
Control Group
n=79 Participants
The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
Total
n=160 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
74 Participants
n=5 Participants
77 Participants
n=7 Participants
151 Participants
n=5 Participants
Age, Categorical
>=65 years
7 Participants
n=5 Participants
2 Participants
n=7 Participants
9 Participants
n=5 Participants
Age, Continuous
45.9 years
STANDARD_DEVIATION 13.8 • n=5 Participants
45.1 years
STANDARD_DEVIATION 13.4 • n=7 Participants
45.5 years
STANDARD_DEVIATION 13.5 • n=5 Participants
Sex: Female, Male
Female
31 Participants
n=5 Participants
39 Participants
n=7 Participants
70 Participants
n=5 Participants
Sex: Female, Male
Male
50 Participants
n=5 Participants
40 Participants
n=7 Participants
90 Participants
n=5 Participants
Region of Enrollment
Germany
81 participants
n=5 Participants
79 participants
n=7 Participants
160 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline and 6 months

Difference between baseline A1c and A1c at 6 month follow up. Equivalent effect on glycemic control measured by A1c (non-inferiority). In case of-non-inferiority test of superiority.

Outcome measures

Outcome measures
Measure
PRIMAS Group
n=75 Participants
PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
Control Group
n=74 Participants
The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
Changes in Glycemic Control Measured by A1c
-0.4 Changes in A1c in percentage points
Standard Deviation 1.0
0.0 Changes in A1c in percentage points
Standard Deviation 0.6

SECONDARY outcome

Timeframe: 6 month

To assess knowledge among insulin-treated diabetes patients, participants completed a new developed 11-item diabetes knowledge score. Each item had to be answered by selecting the correct answer from multiple choices. The numbers of correct answers are summed up; thus, the range of the diabetes knowledge score is between 0 and 11.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 month

The hypoglycemia awareness questionnaire provides a score indicating the severity of hypoglycaemia unawareness. This scale ranges from 0 (maximum hypoglycaemia awareness) to 7 (minimum hypoglycaemia awareness), where a score of 4 suggests reduced hypoglycaemia awareness.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 month follow up

Empowerment was measured by a German version of the Diabetes Empowerment Scale, a measure of diabetes-related psychosocial self-efficacy.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 month

The Summary of Diabetes Self-Care Activities (SDSCA) measure is a self-report measure of diabetes self-management assessing several aspects of the diabetes regimen.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 month follow up

Diabetes related distress was assessed by a German version of the Diabetes Distress Scale (DDS). The DDS is a 17-item self-report scale for the assessment of emotional burdens in diabetes treatment in both type 1 and type 2 diabetes.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 month follow up

Depressive symptoms were assessed using the German version of the Centre for Epidemiologic Studies Depression Scale (CES-D), an instrument for measuring number and severity of depressive symptoms.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 Month Follow up

A German version of the Diabetes Self-efficacy Scale was used to assess diabetes specific self-efficacy.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 Month Follow up

Satisfaction with current diabetes treatment was assessed by a diabetes satisfaction questionnaire developed by Kulzer et al. This questionnaire uncovers problems in dealing with diabetes, also. A high score indicates dissatisfaction with insulin therapy.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 month Follow up

Patients satisfaction with the diabetes education programs was assessed using a self-constructed 12-item scale on specific questions regarding contents and performance of the training. Response mode was a scale ranging from 4 (apply very strong) to 0 (apply not at all). Additionally, patients were asked to give an overall grade for their course ranging from 1 (very good) to 6 (unsatisfactory).

Outcome measures

Outcome data not reported

Adverse Events

PRIMAS Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Norbert Hermanns, PhD

Forschungsinstitut der Diabetes Akademie Mergentheim

Phone: +49 7931 594

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place